![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, November 12, 2017 7:27:53 PM
People seem to forget our biggest study is 20 people for our phase 1/2 in hip fracture. We have NO evidence with any substantial numbers with humans. You can enjoy phase 3 trials starting, but in essence, they are with phase 2 numbers. Our results in the first actual study with some significant numbers will only come from the IC trial early next year.
So until we get those numbers from 172 subjects from I/C, we are in limbo imo. So until those numbers are released, we really are just a phase 2 at most, company when it comes to all else aside from ARS trial. Maybe that's the reason our price is where we are at. Just thought of that this evening unfortunately. Each phase eliminates a vast proportion of candidates, so until we get those results early next year, we will remain so. Unless ARS kicks in.
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM